A research team from the UCLA Health Jonsson Comprehensive Cancer Center, the University of Texas MD Anderson Cancer Center, and collaborators have demonstrated that a novel topical BRAF inhibitor gel ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...

LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...

Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life Acne-like skin rash is a common side effect from colorectal ...

Please provide your email address to receive an email when new articles are posted on . ATR-04 has received a fast track designation from the FDA for epidermal growth factor receptor ...

Patients who are prescribed antibiotics during immune checkpoint blockade therapy for solid tumors face a heightened risk for ...

ATR04-484 is a live biotherapeutic product targeting EGFR inhibitor-associated rashes in cancer patients, containing a modified Staphylococcus epidermidis strain. EGFR inhibitors, used in treating ...

Persistent itching can sometimes signal serious illness, including cancer. Oncologist Dr Amit Garg highlights four ...

"Due to the widespread use of EGFR inhibitors for cancer treatment and the frequent occurrence of dermal toxicities, many patients do not receive optimal cancer therapy. This is often because the ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...